O	0	7	AVE8062	AVE8062	NN	B-NP
O	7	8	:	:	:	O
O	9	10	a	a	DT	B-NP
O	11	14	new	new	JJ	I-NP
O	15	29	combretastatin	combretastatin	NN	I-NP
O	30	40	derivative	derivative	JJ	I-NP
B-Multi-tissue_structure	41	49	vascular	vascular	JJ	I-NP
O	50	60	disrupting	disrupting	NN	I-NP
O	61	66	agent	agent	NN	I-NP
O	66	67	.	.	.	O

O	68	80	Angiogenesis	Angiogenesis	NN	B-NP
O	81	84	has	have	VBZ	B-VP
O	85	87	an	an	DT	B-NP
O	88	97	essential	essential	JJ	I-NP
O	98	102	role	role	NN	I-NP
O	103	105	in	in	IN	B-PP
O	106	115	promoting	promote	VBG	B-VP
O	116	119	and	and	CC	I-VP
O	120	130	supporting	support	VBG	I-VP
B-Cancer	131	136	tumor	tumor	NN	B-NP
O	137	143	growth	growth	NN	I-NP
O	144	147	and	and	CC	O
O	148	150	it	it	PRP	B-NP
O	151	153	is	be	VBZ	B-VP
O	154	156	an	an	DT	B-NP
O	157	166	important	important	JJ	I-NP
O	167	178	therapeutic	therapeutic	JJ	I-NP
O	179	185	target	target	NN	I-NP
O	185	186	.	.	.	O

O	187	190	The	The	DT	B-NP
B-Multi-tissue_structure	191	196	tumor	tumor	NN	I-NP
I-Multi-tissue_structure	197	205	vascular	vascular	JJ	I-NP
I-Multi-tissue_structure	206	213	network	network	NN	I-NP
O	214	216	is	be	VBZ	B-VP
O	217	220	the	the	DT	B-NP
O	221	227	result	result	NN	I-NP
O	228	230	of	of	IN	B-PP
O	231	234	pro	pro	AFX	B-NP
O	234	235	-	-	HYPH	I-NP
O	235	245	angiogenic	angiogenic	JJ	I-NP
O	246	249	and	and	CC	I-NP
O	250	260	inhibitory	inhibitory	JJ	I-NP
O	261	268	factors	factor	NNS	I-NP
O	269	271	as	as	RB	B-CONJP
O	272	276	well	well	RB	I-CONJP
O	277	279	as	as	IN	I-CONJP
O	280	282	of	of	IN	B-PP
O	283	286	the	the	DT	B-NP
O	287	298	interaction	interaction	NN	I-NP
O	299	306	between	between	IN	B-PP
B-Cell	307	318	endothelial	endothelial	JJ	B-NP
I-Cell	319	324	cells	cell	NNS	I-NP
O	325	328	and	and	CC	O
B-Cellular_component	329	342	extracellular	extracellular	JJ	B-NP
I-Cellular_component	343	349	matrix	matrix	NN	I-NP
O	349	350	.	.	.	O

O	351	360	Different	Different	JJ	B-NP
O	361	375	antiangiogenic	antiangiogenic	JJ	I-NP
O	376	388	therapeutics	therapeutic	NNS	I-NP
O	389	393	have	have	VBP	B-VP
O	394	398	been	be	VBN	I-VP
O	399	408	developed	develop	VBN	I-VP
O	409	411	to	to	TO	I-VP
O	412	419	improve	improve	VB	I-VP
B-Cancer	420	425	tumor	tumor	NN	B-NP
O	426	433	control	control	NN	I-NP
O	434	441	through	through	IN	B-PP
B-Multi-tissue_structure	442	450	vascular	vascular	JJ	B-NP
O	450	451	-	-	HYPH	I-NP
O	451	460	targeting	target	VBG	B-VP
O	461	467	agents	agent	NNS	B-NP
O	468	469	(	(	(	O
O	469	472	VTA	VTA	NN	B-NP
O	472	473	)	)	)	O
O	473	474	.	.	.	O

O	475	479	VTAs	VTA	NNS	B-NP
O	480	483	can	can	MD	B-VP
O	484	486	be	be	VB	I-VP
O	487	494	divided	divide	VBN	I-VP
O	495	499	into	into	IN	B-PP
O	500	503	two	two	CD	B-NP
O	504	510	groups	group	NNS	I-NP
O	510	511	:	:	:	O
O	512	526	antiangiogenic	antiangiogenic	JJ	B-NP
O	527	533	agents	agent	NNS	I-NP
O	534	537	and	and	CC	O
B-Multi-tissue_structure	538	546	vascular	vascular	JJ	B-NP
O	546	547	-	-	HYPH	I-NP
O	547	557	disrupting	disrupt	VBG	I-NP
O	558	564	agents	agent	NNS	I-NP
O	565	566	(	(	(	O
O	566	570	VDAs	VDA	NNS	B-NP
O	570	571	)	)	)	O
O	571	572	.	.	.	O

O	573	577	VTAs	VTA	NNS	B-NP
O	578	585	inhibit	inhibit	VBP	B-VP
O	586	594	specific	specific	JJ	B-NP
O	595	602	factors	factor	NNS	I-NP
O	603	611	required	require	VBN	B-VP
O	612	614	to	to	TO	B-VP
O	615	621	induce	induce	VB	I-VP
O	622	625	and	and	CC	I-VP
O	626	632	direct	direct	VB	I-VP
O	633	636	the	the	DT	B-NP
O	637	647	angiogenic	angiogenic	JJ	I-NP
O	648	655	process	process	NN	I-NP
O	655	656	,	,	,	O
O	657	661	with	with	IN	B-PP
O	662	667	major	major	JJ	B-NP
O	668	676	activity	activity	NN	I-NP
O	677	684	against	against	IN	B-PP
O	685	690	small	small	JJ	B-NP
B-Cancer	691	696	tumor	tumor	NN	I-NP
I-Cancer	697	703	masses	mass	NNS	I-NP
O	704	707	and	and	CC	B-PP
O	708	710	at	at	IN	B-PP
O	711	714	the	the	DT	B-NP
B-Tissue	715	720	tumor	tumor	NN	I-NP
I-Tissue	721	730	periphery	periphery	NN	I-NP
O	730	731	,	,	,	O
O	732	744	encompassing	encompass	VBG	B-VP
O	745	755	monoclonal	monoclonal	JJ	B-NP
O	756	766	antibodies	antibody	NNS	I-NP
O	767	770	and	and	CC	O
O	771	776	small	small	JJ	B-NP
O	777	786	molecules	molecule	NNS	I-NP
O	787	797	inhibitors	inhibitor	NNS	I-NP
O	798	800	of	of	IN	B-PP
O	801	804	the	the	DT	B-NP
O	805	813	tyrosine	tyrosine	NN	I-NP
O	814	820	kinase	kinase	NN	I-NP
O	821	827	domain	domain	NN	I-NP
O	828	830	of	of	IN	B-PP
O	831	834	the	the	DT	B-NP
O	835	839	VEGF	VEGF	NN	I-NP
O	840	848	receptor	receptor	NN	I-NP
O	848	849	.	.	.	O

O	850	854	VDAs	VDA	NNS	B-NP
O	855	867	specifically	specifically	RB	B-NP
O	868	874	target	target	NN	I-NP
O	875	878	and	and	CC	I-NP
O	879	886	destroy	destroy	NN	I-NP
O	887	891	well	well	RB	B-ADVP
O	891	892	-	-	HYPH	B-VP
O	892	903	established	establish	VBN	B-NP
B-Multi-tissue_structure	904	909	tumor	tumor	NN	I-NP
I-Multi-tissue_structure	910	917	vessels	vessel	NNS	I-NP
O	918	922	with	with	IN	B-PP
O	923	931	ischemia	ischemia	NN	B-NP
O	932	935	and	and	CC	I-NP
O	936	947	destruction	destruction	NN	I-NP
O	948	950	of	of	IN	B-PP
O	951	956	large	large	JJ	B-NP
B-Cancer	957	963	masses	mass	NNS	I-NP
O	964	968	with	with	IN	B-PP
O	969	976	central	central	JJ	B-NP
O	977	988	hemorrhagic	hemorrhagic	JJ	I-NP
O	989	997	necrosis	necrosis	NN	I-NP
O	998	1001	and	and	CC	I-NP
O	1002	1010	survival	survival	NN	I-NP
O	1011	1013	of	of	IN	B-PP
O	1014	1015	a	a	DT	B-NP
O	1016	1020	thin	thin	JJ	I-NP
B-Cancer	1021	1031	peripheral	peripheral	JJ	I-NP
I-Cancer	1032	1037	tumor	tumor	NN	I-NP
I-Cancer	1038	1043	layer	layer	NN	I-NP
O	1043	1044	.	.	.	O

O	1045	1049	VDAs	VDA	NNS	B-NP
O	1050	1053	can	can	MD	B-VP
O	1054	1056	be	be	VB	I-VP
O	1057	1064	divided	divide	VBN	I-VP
O	1065	1069	into	into	IN	B-PP
O	1070	1079	biologics	biologic	NNS	B-NP
O	1079	1080	,	,	,	O
O	1081	1085	such	such	JJ	B-PP
O	1086	1088	as	as	IN	I-PP
O	1089	1095	ligand	ligand	NN	B-NP
O	1095	1096	-	-	HYPH	O
O	1096	1101	based	base	VBN	B-VP
O	1101	1102	,	,	,	O
O	1103	1106	and	and	CC	O
O	1107	1112	small	small	JJ	B-NP
O	1112	1113	-	-	HYPH	I-NP
O	1113	1121	molecule	molecule	NN	I-NP
O	1122	1128	agents	agent	NNS	I-NP
O	1128	1129	;	;	:	O
O	1130	1134	this	this	DT	B-NP
O	1135	1141	second	second	JJ	I-NP
O	1142	1147	group	group	NN	I-NP
O	1148	1156	includes	include	VBZ	B-VP
O	1157	1162	small	small	JJ	B-NP
O	1162	1163	-	-	HYPH	I-NP
O	1163	1171	molecule	molecule	NN	I-NP
O	1172	1176	VDAs	VDA	NNS	I-NP
O	1177	1181	like	like	IN	B-PP
O	1182	1192	flavonoids	flavonoid	NNS	B-NP
O	1192	1193	,	,	,	O
O	1194	1198	such	such	JJ	B-PP
O	1199	1201	as	as	IN	I-PP
O	1202	1203	5	5	CD	B-NP
O	1203	1204	,	,	,	I-NP
O	1204	1205	6	6	CD	I-NP
O	1205	1206	-	-	HYPH	I-NP
O	1206	1224	dimethylxanthenone	dimethylxanthenone	NN	I-NP
O	1224	1225	-	-	HYPH	I-NP
O	1225	1226	4	4	CD	I-NP
O	1226	1227	-	-	HYPH	I-NP
O	1227	1233	acetic	acetic	JJ	I-NP
O	1234	1238	acid	acid	NN	I-NP
O	1239	1240	(	(	(	O
O	1240	1245	DMXAA	DMXAA	NN	B-NP
O	1245	1246	)	)	)	O
O	1246	1247	,	,	,	O
O	1248	1251	and	and	CC	O
B-Cellular_component	1252	1263	microtubule	microtubule	NN	B-NP
O	1263	1264	-	-	HYPH	O
O	1264	1277	destabilizing	destabilize	VBG	B-NP
O	1278	1284	agents	agent	NNS	I-NP
O	1284	1285	.	.	.	O

O	1286	1288	In	In	IN	B-PP
O	1289	1293	this	this	DT	B-NP
O	1294	1300	review	review	NN	I-NP
O	1301	1303	we	we	PRP	B-NP
O	1304	1308	will	will	MD	B-VP
O	1309	1316	discuss	discuss	VB	I-VP
O	1317	1320	the	the	DT	B-NP
O	1321	1330	mechanism	mechanism	NN	I-NP
O	1331	1333	of	of	IN	B-PP
O	1334	1340	action	action	NN	B-NP
O	1340	1341	,	,	,	O
O	1342	1344	as	as	RB	B-CONJP
O	1345	1349	well	well	RB	I-CONJP
O	1350	1352	as	as	IN	I-CONJP
O	1353	1356	the	the	DT	B-NP
O	1357	1368	preclinical	preclinical	JJ	I-NP
O	1369	1372	and	and	CC	I-NP
O	1373	1381	clinical	clinical	JJ	I-NP
O	1382	1389	results	result	NNS	I-NP
O	1389	1390	,	,	,	O
O	1391	1393	of	of	IN	B-PP
O	1394	1397	one	one	CD	B-NP
O	1398	1400	of	of	IN	B-PP
O	1401	1404	the	the	DT	B-NP
O	1405	1409	most	most	RBS	I-NP
O	1410	1419	promising	promising	JJ	I-NP
O	1420	1431	antitubulin	antitubulin	JJ	I-NP
O	1432	1438	agents	agent	NNS	I-NP
O	1438	1439	:	:	:	O
O	1440	1443	the	the	DT	B-NP
O	1444	1458	combretastatin	combretastatin	NN	I-NP
O	1459	1461	A4	A4	NN	I-NP
O	1461	1462	-	-	HYPH	B-NP
O	1462	1471	phosphate	phosphate	NN	I-NP
O	1472	1482	derivative	derivative	NN	I-NP
O	1482	1483	,	,	,	O
O	1484	1492	AVE8062A	AVE8062A	NN	B-NP
O	1492	1493	.	.	.	O

